top
Please input keywords
YH013


YH013 is an EGFR x MET bispecific ADC which is intended for the treatment of solid tumor. The bispecific antibody backbone is produced by RenLite mice of fully human antibodies with a common light chain. It has a monoclonal antibody structure, which makes purification and drug conjugation easy. YH013 is currently at discovery stage.


Preclinical studies have shown the following findings:

1. EGFR x MET bispecific antibody (YH013 unconjugated, YH013 unconj. for short) showed higher binding ability than parental monoclonal and monovalent antibodies that recognize single target EGFR or MET in antigen double-positive NCI-H1975 (EGFR+ MET+) cancer cells.


from clipboard


Figure 1. Tumor cell line binding


2. YH013 unconj. has superior endocytosis activity over parental monoclonal and monovalent antibodies in antigen double-positive NCI-H1975 cancer cells.

from clipboard

Figure 2. Tumor cell endocytosis


3. YH013 showed outstanding tumor inhibition in CDX and PDX models.


from clipboard


Figure 3. YH013 induced dose-dependent tumor inhibition in NSCLC CDX(B-NDG + NCI-H1975)and showed robust anti-tumor effect in pancreatic PDX(B-NDG + BP209)model.


4. YH013 demonstrated CMC-suitable physiochemical properties.


from clipboard


Targets

EGFR (epidermal growth factor receptor) is a transmembrane protein with cytoplasmic kinase activity that transduces important growth factor signaling from the extracellular milieu to the cell.

MET (mesenchymal-epithelial transition factor) gene amplification constitutes the most frequent cause of bypass signaling activation as an acquired resistance mechanism to EGFR TKIs.

EGFR and MET co-express on many tumor types. In 2021, Amivantamab (EGFR x MET bispecific antibody) was approved by FDA.


Poster Downloads

World ADC San Diego2022:YH013, a fully-human EGFR x MET bispecific ADC exhibits outstanding specificity and anti-tumor efficacy

PEGS EUROPE 2022: YH013, a fully-human EGFR x c-MET bispecific ADC exhibits outstanding specificity and anti-tumor efficacy

naver-site-verification: naver8a6b0412e3d2d9dd38f1684b831435ac.html